Efficacy of Lebrikizumab in Patients with Atopic Dermatitis and Atopic Comorbidities: Pooled Results From 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
Authors: Ellen R. Sher, Mark Boguniewicz, Alexandra K. Golant, Marjolein de Bruin-Weller, Jose-Manuel Carrascosa, Jinglin Zhong, Zach Dawson, Amber Reck Atwater, Kimberly Siu, Jacob P. Thyssen
< PREVIOUS POSTER NEXT POSTER >
